News
Wells Fargo Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $170
24 Apr 24
News, Upgrades, Price Target, Analyst Ratings
Oppenheimer Maintains Outperform on Neurocrine Biosciences, Maintains $200 Price Target
24 Apr 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $150 Price Target
24 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
23 Apr 24
Biotech, Large Cap, News, Health Care, Movers, Trading Ideas, General
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $147 Price Target
17 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Sentia Medical Sciences Further Extends Research Collaboration With Neurocrine Biosciences To Discover Novel CRF Peptides
16 Apr 24
News
Nxera Pharma's NBI-1117568, Backed by Neurocrine Biosciences, Successfully Completes Long-Term Preclinical Toxicity Program
16 Apr 24
News
Where Neurocrine Biosciences Stands With Analysts
10 Apr 24
Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Maintains $155 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating Effects Of NBI-1065890, A Second-Generation VMAT2 Inhibitor, In Healthy Adults
28 Mar 24
Biotech, News, FDA, General
JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $158
20 Mar 24
News, Price Target, Analyst Ratings
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
19 Mar 24
Analyst Color, Biotech, Equities, News, Health Care, Price Target, Initiation, Analyst Ratings, Movers, Trading Ideas, General
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
13 Mar 24
Analyst Ratings
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
13 Mar 24
Analyst Ratings
Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $200
13 Mar 24
News, Price Target, Analyst Ratings
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
12 Feb 24
Analyst Color, Long Ideas, News, Upgrades, Price Target, Top Stories, Analyst Ratings, Movers, Trading Ideas
Citigroup Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $140
8 Feb 24
News, Price Target, Analyst Ratings
Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $140-Report released on 7th February 2024
8 Feb 24
News, Price Target, Analyst Ratings
Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
8 Feb 24
Analyst Ratings
Wells Fargo Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $140
8 Feb 24
News, Price Target, Analyst Ratings
Press releases
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
24 Apr 24
Press Releases
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
16 Apr 24
Press Releases
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16 Apr 24
Press Releases
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
10 Apr 24
Press Releases
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
3 Apr 24
Press Releases
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
28 Mar 24
Press Releases
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
11 Mar 24
Press Releases
Neurocrine Biosciences to Participate at Investor Conferences in March
27 Feb 24
Press Releases
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
7 Feb 24
Earnings, Press Releases